Germany· DE-A57-1fe75304f9bd46ba
Patentblau V Azultis
A medicinal product containing patent blue v (e131), registered in Germany by Provepharm Sas.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Patent Blue V (E131)
- Manufacturer
- Provepharm Sas
- Country
- Germany (DE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- August 5, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Patent blue v (e131) in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomPatent blue V 2.5% solution for injection 2ml ampoulesImported (France)
- BelgiumBleu Patente V Guerbet 2.5 g/100 mlGuerbet
- SpainAZUL PATENTE AZULTIS 25 MG/ML SOLUCION INYECTABLE EFGProvepharm
- FranceBLEU PATENTE V SODIQUE GUERBET 2,5 POUR CENT, solution injectableGUERBET
- NorwayBleu Patente V guerbetGuerbet
Authorised across Europe · EMA
The same active substance is authorised in 8 EEA countries. Names it is sold under:
- Austria · Patentblau V Azultis
- Belgium · Bleu Patenté V Guerbet
- Spain · Azul Patente Azultis
- France · Bleu Patente V Sodique Azultis, Bleu Patente V Sodique Guerbet
- Hungary · Patent Blue V Sodium Azultis Provepharm, Patentblue Guerbet
- Luxembourg · Bleu Patenté V Guerbet
- Netherlands · Bleu Patente V Guerbet, Patentblauw V Azultis
- Slovakia · Patentblau V Guerbet
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/243f6b15-8c81-4134-b26f-44d2ba2bd1b3 GET /v1/drugs/243f6b15-8c81-4134-b26f-44d2ba2bd1b3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Intraarterial Use, Subcutaneous Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Patent Blue V (E131)",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about patent blue v (e131).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.